Triple-Negative Breast Cancer Treatment Market: Inclination of Leading Players Towards Research and Development Activities to Bring More Revenues
Triple-negative breast cancer is a type of cancer that does not have receptors for the hormones oestrogen and progesterone or the protein HER2. Triple-negative breast cancer is a rare type of cancer. About 10–20% of breast cancers are found to be triple negative. Triple-negative breast cancer does not responds to hormonal therapy or therapies that target HER2 receptors such as Herceptin (trastuzumab). The treatment combines surgery, radiotherapy and chemotherapy. To comprehend recent trends and factors influencing growth of global triple-negative...
View full press release